Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial - Petersenn, S; Schopohl, J; Barkan, A; Mohideen, P; Colao, A; Abs, R; Buchelt, A; Ho, Y Y; Hu, K; Farrall, A J; Melmed, S; Biller, B M; Pasireotide Acromegaly Study Group (J Clin Endocrinol Metab, 2010)